Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Doxycycline Placebo Clear all
Completed Phase 4 Interventional Results available

Oracea Soolantra Association in Participants With Severe Rosacea

NCT03075891
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules, Oral placebo capsules
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Fort Smith, Arkansas • Sacramento, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 27, 2026, 7:21 AM EDT
Terminated Phase 2 Interventional Results available

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT02569437
View directory record Official record
Conditions
Polyp of Nasal Sinus
Interventions
Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

Management of Etonogestrel Subdermal Implant-related Bleeding

NCT01658995
View directory record Official record
Conditions
ESI-related Bleeding
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Petra M. Casey
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease

NCT00001101
View directory record Official record
Conditions
Lyme Disease
Interventions
ceftriaxone, doxycycline
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00612573
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years to 45 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
23
States / cities
Encino, California • Fremont, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

NCT01160640
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Ceftriaxone, Doxycycline, Metronidazole, Placebo Oral Capsule
Drug
Lead sponsor
Harold Wiesenfeld
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 27, 2026, 7:21 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

NCT01935622
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Systolic Heart Failure (NYHA II-III)
Interventions
Doxycycline, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 27, 2026, 7:21 AM EDT
Active, not recruiting Phase 2 Interventional

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

NCT05382208
View directory record Official record
Conditions
Emphysema, HIV
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Continuous Oral Contraceptives and Doxycycline

NCT00480532
View directory record Official record
Conditions
Contraceptives, Oral
Interventions
Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Sep 27, 2026, 7:21 AM EDT
Recruiting Phase 2 Interventional

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123
View directory record Official record
Conditions
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Doxycycline Hyclate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 27, 2026, 7:21 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Treatments on Atopic Dermatitis

NCT01631617
View directory record Official record
Conditions
Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases
Interventions
Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 50 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 2Phase 3 Interventional

Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

NCT01782989
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 27, 2026, 7:21 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline

NCT03968562
View directory record Official record
Conditions
Hives
Interventions
2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 3 Interventional

Doxycycline and OA Progression

NCT00000403
View directory record Official record
Conditions
Osteoarthritis
Interventions
Doxycycline
Drug
Lead sponsor
Indiana University
Other
Eligibility
45 Years to 64 Years · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
6
States / cities
Birmingham, Alabama • Tucson, Arizona • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions

NCT02756403
View directory record Official record
Conditions
First Trimester Abortion
Interventions
Azithromycin, Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

NCT05296629
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
27
States / cities
Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

NCT01308619
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Hot Springs, Arkansas • San Diego, California • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 2 Interventional

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

NCT03637400
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Skin Infection
Interventions
TMP-SMX, DOXY
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
9 Years to 85 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Sylmar, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

NCT00351273
View directory record Official record
Conditions
Arthritis, Reactive, Reiter Disease
Interventions
Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Tampa, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 2 Interventional

A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period

NCT00439400
View directory record Official record
Conditions
Dry Eye
Interventions
doxycycline, placebo
Drug
Lead sponsor
Alacrity Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Timeline
2007
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 27, 2026, 7:21 AM EDT
Withdrawn Not applicable Interventional

Study of NanoDOX Hydrogel vs Placebo for Dehisced Surgical Wounds

NCT01547325
View directory record Official record
Conditions
Dehisced Surgical Wounds
Interventions
NanoDOX 1% doxycycline monohydrate Hydrogel, placebo hydrogel
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 1 Interventional

A Trial of Doxycycline in Renal Disease

NCT02753426
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiorenal Syndrome
Interventions
Doxycycline, Placebo (for Doxycycline)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 27, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

NCT00764361
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
doxycycline, placebo gel
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 27, 2026, 7:21 AM EDT